Relay Therapeutics, Inc. (RLAY)

A. Company Overview

Relay Therapeutics, Inc. is a clinical-stage precision medicine company that is at the forefront of innovation in drug discovery. The company aims to revolutionize the process of identifying and developing therapeutics by integrating state-of-the-art computational and experimental technologies. The overarching goal is to deliver life-changing therapies to patients, particularly those suffering from serious and life-threatening conditions.

The unique Dynamo™ platform developed by Relay Therapeutics represents a novel approach to drug discovery, focusing on enhancing the specificity and potency of small molecules to effectively target previously intractable proteins. This platform applies insights derived from fundamental understandings of protein dynamics, which allows for a shift from traditional static protein models to a dynamic perspective that captures the behavior of proteins in their natural state through a method termed Motion-Based Drug Design®.

The company is currently targeting precision oncology and genetic diseases, areas where there is a strong link between genetic alterations and disease pathology. Relay Therapeutics utilizes molecular diagnostics to identify patients who are most likely to benefit from its product candidates, thereby increasing the likelihood of successful clinical translation.

B. Focus Areas

Precision Medicine

Precision medicine serves as the cornerstone of Relay Therapeutics' strategy, emphasizing individualized treatment frameworks that leverage genetic information to dictate therapeutic choices. The company is primarily focused on conditions where specific genetic mutations play a decisive role in disease manifestation, thereby allowing interventions at the molecular level that align with current understandings of genetics and protein functions.

Relay Therapeutics aims to directly address gaps in conventional drug discovery, specifically in precision oncology and genetic diseases. Applications of its technology are expected to facilitate more targeted interventions, with a potential expansion into addressing genetic diseases, thereby allowing the Dynamo platform to serve in diverse therapeutic contexts.

Motion-Based Drug Design

The Motion-Based Drug Design® framework involves using the insights gained from the Dynamo platform to understand protein conformational dynamics. This methodology enables the identification and optimization of therapeutic candidates with greater specificity, addressing limitations seen with traditional drug discovery approaches that rely on static images of target proteins.

C. Pipeline of Product Candidates

Relay Therapeutics has built a robust pipeline aimed at advancing product candidates against genetically validated targets. Significant focus is placed on:

RLY-2608

RLY-2608 is a pan-mutant, isoform-selective inhibitor of phosphoinositide 3-kinase alpha (PI3Kα), which is frequently mutated in various cancers. The ReDiscover Trial, initiated in December 2021, assesses RLY-2608's safety and efficacy as a single agent and in combination with other treatments like fulvestrant for patients with HR+, HER2– breast cancer featuring specific PI3Kα mutations. Initial clinical data exhibit promising interim efficacy and safety profiles.

Lirafugratinib (RLY-4008)

Lirafugratinib is a selective FGFR2 inhibitor, currently evaluated in the ReFocus Trial. Preclinical and preliminary clinical data suggest that it offers improved specificity in targeting FGFR2 alterations that are significant in certain tumors. The trial aims to delineate the therapeutic potential across multiple cohorts with varying FGFR2 alterations, addressing unmet needs in patient populations.

Migoprotafib (GDC-1971)

Originally designated as RLY-1971, this investigational drug targets SHP2, a protein that plays a critical role in cancer cell survival and growth. The development of migoprotafib is being guided by a collaboration with Genentech that focuses on its use in combination with other agents targeting oncogenic pathways.

D. Technology Platform

Dynamo™ Platform

The Dynamo platform combines various computational and experimental technologies to derive insights into protein structure and functionality. Unlike conventional drug discovery methods that deal with static structures, Dynamo emphasizes the dynamic movement of proteins, allowing for more informed and innovative therapeutic design. This platform's capabilities have grown and evolved, encompassing sophisticated molecular dynamics simulations, automated chemical design, and machine learning technologies.

E. Strategic Collaborations

Relay Therapeutics has strategically partnered with D.E. Shaw Research to advance its computational modeling capabilities, specifically in the area of protein dynamics. Furthermore, collaborations with major pharmaceutical entities, such as Genentech, enhance its developmental endeavors and expand its potential market reach. Such collaborations ensure that Relay Therapeutics remains at the cutting edge of drug discovery innovation while facilitating the rapid progression of its product candidates through clinical trials.

F. Competitive Landscape

In the fast-evolving pharmaceutical landscape, Relay Therapeutics faces competition from multiple sectors, including biotech firms, pharmaceutical companies, and academic research institutions. However, the company posits significant advantages due to its integrated approach that combines deep insights into protein dynamics with cutting-edge technology. This comprehensive integration positions Relay Therapeutics to address traditionally challenging targets and provide novel therapeutics that demonstrate improved specificity and potency.